EIDD-2801 is an oral bioavailable prodrug of the ribonucleoside analogue EIDD-1931. EIDD-2801 has broad-spectrum antiviral activity against influenza virus and a variety of coronaviruses. Molnupiravir is an antiviral medication that has gained attention for its potential use in treating COVID-19 and other viral infections.
Molnupiravir was originally developed as a potential treatment for influenza. However, its broad-spectrum antiviral activity has led to investigations into its effectiveness against other RNA viruses, including coronaviruses.
|
Product Name
|
EIDD-2801 |
|
CAS
|
2349386 89 4 |
|
Appearance
|
White powder
|
|
MF
|
C13H19N3O7 |
|
Molecular Weight
|
329.31 |
|
Purity
|
99% min
|
|
Storage
|
Keep in a cool, dry, dark location in a tightly sealed container or cylinder
|
|
Shelf Life
|
24 Months
|
Molnupiravir gained significant attention during the COVID-19 pandemic as a potential oral antiviral treatment for SARS-CoV-2, the virus that causes COVID-19. Clinical trials have been conducted to evaluate its efficacy and safety in COVID-19 patients.
Studies have shown that Molnupiravir can reduce the duration of viral shedding and symptoms in COVID-19 patients when administered early in the course of the infection. It is believed to help limit the spread of the virus within the body and potentially reduce the severity of the illness.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
